Analyst Ratings For Boston Scientific Corporation (NYSE:BSX)
Today, Morgan Stanley raised its price target on Boston Scientific Corporation (NYSE:BSX) to $38.00 per share.
There are 16 Buy Ratings, 3 Strong Buy Ratings, 3 Hold Ratings, no Sell Ratings on the stock.
The current consensus rating on Boston Scientific Corporation (NYSE:BSX) is Buy with a consensus target price of $33.8182 per share, a potential 1.49% downside.
Some recent analyst ratings include
- 7/6/2018-Needham & Company LLC Reiterated Rating of Strong-Buy.
- 6/27/2018-Sanford C. Bernstein initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Boston Scientific Corporation (NYSE:BSX)
Boston Scientific Corporation (NYSE:BSX) has insider ownership of 0.73% and institutional ownership of 88.91%.
- On 7/10/2018 Jeffrey B. Mirviss, SVP, sold 33,512 with an average share price of $34.00 per share and the total transaction amounting to $1,139,408.00.
- On 7/2/2018 David A Pierce, EVP, sold 5,000 with an average share price of $32.42 per share and the total transaction amounting to $162,100.00.
- On 6/16/2018 John E. Sununu, Director, bought 30 with an average share price of $27.80 per share and the total transaction amounting to $834.00.
- On 6/14/2018 Jeffrey B. Mirviss, SVP, sold 19,323 with an average share price of $32.64 per share and the total transaction amounting to $630,702.72.
- On 6/11/2018 Kevin J Ballinger, EVP, sold 68,486 with an average share price of $34.12 per share and the total transaction amounting to $2,336,742.32.
- On 6/7/2018 David A Pierce, EVP, sold 1,650 with an average share price of $30.83 per share and the total transaction amounting to $50,869.50.
- On 6/1/2018 David A Pierce, EVP, sold 5,000 with an average share price of $30.58 per share and the total transaction amounting to $152,900.00.
About Boston Scientific Corporation (NYSE:BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Recent Trading Activity for Boston Scientific Corporation (NYSE:BSX)
Shares of Boston Scientific Corporation closed the previous trading session at 34.43 up +0.11 0.32% with 34.08 shares trading hands.
